

101.561-24/03 – including *Taq* polymerase
 101.561-24u/03u – without *Taq* polymerase

Visit www.caredx.com for
 "Instructions for Use" (IFU)

Lot No.: **5S3**

Lot-specific information

Declaration of Conformity

Product name: Olerup SSP® HLA-B*51
Product number: 101.561-24/24u, -03/03u
Lot number: 5S3

Intended use: HLA-B*51 histocompatibility testing

Manufacturer: CareDx AB
 Franzengatan 5
 SE-112 51 Stockholm, Sweden
Phone: +46-8-508 939 00
Fax: +46-8-717 88 18

We, CareDx AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) EN ISO 13485:2016, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices, Annex II List B, conformity assessed using Annex IV, as transposed into the national laws of the Member States of the European Union.

The Technical Documentation File is maintained at CareDx AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

The Authorized Representative located within the Community is: CareDx AB.

Notified Body: TÜV Rheinland LGA products, Tillystrasse 2, D-90431 Nürnberg, Germany. (Notified Body number: 0197.)

Stockholm, Sweden
 Date:

2023 11 15 /

Susan B

Quality Assurance



0197

For *In Vitro* Diagnostic Use
 MA100 v06 CoA_DoC IVD Annex II List B
 Date: October 2023, Rev. No: 00

101.561-24/03 – including *Taq* polymerase
 101.561-24u/03u – without *Taq* polymerase

Visit www.caredx.com for
 “Instructions for Use” (IFU)

Lot No.: **5S3**

Lot-specific information
CERTIFICATE OF ANALYSIS

Olerup SSP® HLA-B*51

Product number: 101.561-24/03 – including *Taq* pol.
 101.561-24u/03u – without *Taq* pol.
Lot number: 5S3
Expiry date: 2027-10-01
Number of tests: 24 tests – Product No. 101.561-24/24u
 3 tests – Product No. 101.561-03/03u
Number of wells per test: 84+1

Well specifications:

Well No.	Production No.	Well No.	Production No.	Well No.	Production No.
1	2020-210-01	33	2020-210-33	65	2020-210-65
2	2020-210-02	34	2020-210-34	66	2020-210-66
3	2020-210-03	35	2020-210-35	67	2020-210-67
4	2020-210-04	36	2020-210-36	68	2020-210-68
5	2020-210-05	37	2020-210-37	69	2020-210-69
6	2020-210-06	38	2020-210-38	70	2020-210-70
7	2020-210-07	39	2020-210-39	71	2020-210-71
8	2020-210-08	40	2020-210-40	72	2020-210-72
9	2020-210-09	41	2020-210-41	73	2020-210-73
10	2020-210-10	42	2020-210-42	74	2020-210-74
11	2020-210-11	43	2020-210-43	75	2020-210-75
12	2020-210-12	44	2020-210-44	76	2020-210-76
13	2020-210-13	45	2020-210-45	77	2020-210-77
14	2020-210-14	46	2020-210-46	78	2020-210-78
15	2020-210-15	47	2020-210-47	79	2020-210-79
16	2020-210-16	48	2020-210-48	80	2020-210-80
17	2020-210-17	49	2020-210-49	81	2020-210-81
18	2020-210-18	50	2020-210-50	82	2020-210-82
19	2020-210-19	51	2020-210-51	83	2020-210-83
20	2020-210-20	52	2020-210-52	84	2020-210-84
21	2020-210-21	53	2020-210-53		
22	2020-210-22	54	2020-210-54		
23	2020-210-23	55	2020-210-55		
24	2020-210-24	56	2020-210-56		
25	2020-210-25	57	2020-210-57		
26	2020-210-26	58	2020-210-58		
27	2020-210-27	59	2020-210-59		
28	2020-210-28	60	2020-210-60		
29	2020-210-29	61	2020-210-61		
30	2020-210-30	62	2020-210-62		
31	2020-210-31	63	2022-450-63		
32	2020-210-32	64	2020-210-64		

The negative control primer pairs, **Production No. 2023-544-01**, can detect contamination with PCR products diluted 10⁻⁷.



0197

For *In Vitro* Diagnostic Use
 MA100 v06 CoA_DoC IVD Annex II List B
 Date: October 2023, Rev. No: 00

101.561-24/03 – including *Taq* polymerase
101.561-24u/03u – without *Taq* polymerase

Visit www.caredx.com for
“Instructions for Use” (IFU)

Lot No.: **5S3**

Lot-specific information

Results of Quality Control:

No false positive or false negative amplifications
obtained.

Date of approval: 2023-11-14

Approved by:



Production Quality Control



0197

For *In Vitro* Diagnostic Use

MA100 v06 CoA_DoC IVD Annex II List B

Date: October 2023, Rev. No: 00